ArticleDiscover oncology2026
Efficacy comparison of preoperative versus postoperative radiotherapy for rectal cancer: an analysis based on the SEER database.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeFor stage II and III rectal cancer, two commonly used treatment strategies are preoperative radiotherapy (RT) combined with surgery, and surgery combined with postoperative RT. This study aims to systematically compare the efficacy of preoperative RT versus postoperative RT for rectal cancer based on the Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND
methodsCases of rectal cancer were retrieved using SEER ∗ Stat software, including patients who underwent preoperative RT combined with surgery (PreORT group) and those received surgery combined with postoperative RT (PostORT group). Propensity score matching (PSM) was performed via the R software package (version 4.3.1) to balance intergroup differences. Kaplan–Meier curves for overall survival (OS) and cause-specific survival (CSS) were plotted for the cohort before and after PSM using IBM SPSS 23.0.
resultsA total of 22,079 rectal cancer cases were included, with 16,719 in the PreORT group and 5,360 in the PostORT group. Compared with the PostORT group, the PreORT group showed significantly higher 10-year OS (54.5% Vs. 58.9%, P < 0.001) and CSS (64.5% Vs. 67.9%, P < 0.001). However, in the matched cohort, the PostORT group had higher 10-year OS (55.7% Vs. 57.4%, P = 0.038) and CSS (64.8% Vs. 67.5%, P = 0.040).
conclusionWhile the PreORT group exhibited higher OS and CSS in the entire cohort, the PostORT group showed favorable survival outcomes in the matched cohort. However, given that PreORT remains the standard of care and SEER data lack critical clinical variables influencing treatment selection, these findings should be interpreted as hypothesis-generating rather than indicative of a change in clinical practice. Future randomized, multicenter, prospective studies with large sample sizes are therefore warranted to validate these results and identify subgroups most likely to benefit from each approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.